The plasmatic concentration of imatinib will be determined, for each patient, the day of the second sperm recovery to check the efficiency of ATK administration. Blood and lymphatic system disorders. Ages Eligible for Study: Doses of mg or mg should be administered once daily, whereas a daily dose of mg should be administered as mg twice a day, in the morning and in the evening. The median duration of second-line treatment with Imatinib was 64 months. They were receiving imatinib, dasatinib or nilotinib as upfront therapy.
We are sorry !
Musculoskeletal and connective tissue disorders. How you have it You have imatinib as a tablet that you swallow whole, with a glass of water after food. Eckman A, Dobs A Drug-induced gynecomastia. Home Analysis Gleevec Sperm-count-decreased. The main comparison criterion will be the mean difference in sperm concentration before and after the 6 month treatment. Drug Information available for: You usually continue taking imatinib for as long as it works, unless the side effects get too bad.
Imatinib - wikidoc
One open label, multicentre, phase II clinical trial study B was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. The evening brings a chance to socialise and relax away from the hotel. The increase in mean AUC with increasing dose was linear and dose proportional in the range of , mg imatinib after oral administration. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic Myeloid Leukemia. Patient 11, who developed gynecomastia, had only blood samples taken at 0, 3 and 6 months. The median duration of therapy in study B was 6.
FYI - we are expecting in Feb - our first. Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing. You have imatinib as a tablet that you swallow whole, with a glass of water after food. The 23 patients enrolled in this registry received imatinib at a median daily dose of mg range: Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to imatinib exposure.